

## SCIENTIFIC PROGRAM

### SESSION LECTURE

No. 27

Cell Death and Disease

Room: 303AB

Co-Chairs: Quan Chen



Suzanne Cory



Day 2 October 28<sup>th</sup> (Sunday) 13:30 – 17:00

Time	Speaker	Title
13:30-14:00	<b>Suzanne Cory</b> <i>Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia</i>	From Translocation to Therapy: How understanding the BCL-2 cell life/death switch is leading to more effective therapy
14:00-14:15	<b>Shuo Chen</b> <i>University of Oxford, UK</i>	Modular Regulation of p53 DNA Binding by iASPP Imparts Target Selectivity
14:15-14:45	<b>Junying Yuan</b> <i>Harvard Medical School, USA</i>	Regulation of RIPK1 activation in neurodegenerative diseases
14:45-15:15	<b>David Huang</b> <i>Melbourne University, Australia</i>	Targeting BCL2 to treat cancer
15:15-15:30	<b>Tea Break</b>	
15:30-16:00	<b>Seamus J. Martin</b> <i>Trinity College Dublin, Ireland</i>	Stress-induced inflammatory functions of 'death receptors'
16:00-16:30	<b>Quan Chen</b> <i>Institute of Zoology, CAS, China</i>	PGAM5 interacts with Bcl-xL and FUNDC1 to coordinate mitochondrial apoptosis with mitophagy
16:30-17:00	<b>Jialing Lin</b> <i>University of Oklahoma Health Sciences Center, USA</i>	Structure, Function and Regulation of Bcl-2 Family Proteins in Cell Death and Diseases



### Quan Chen

[chenq@ioz.ac.cn](mailto:chenq@ioz.ac.cn)

Dr. Chen as director of the Society of Membrane Biology in the Chinese Society of Biophysics. His research is internationally recognized and he currently serves as an editorial board member for FEBS Letters, Cell Research, JBC, Cell Death & Disease, Open Biology and national journals. He is also the International Affairs committee member of the American Society of Cell Biology, and vice president of the Asian Society of Mitochondrial Research and Medicine. The research in Dr. Chen's laboratory focuses on mitochondrial biology and cancer stem cells.



### Junying Yuan

[junying\\_ng\\_yuan@hms.harvard.edu](mailto:junying_ng_yuan@hms.harvard.edu)

Dr. Yuan carried out her Ph.D thesis work at the Massachusetts Institute of Technology. She was first appointed as Assistant Professor at Harvard Medical School in 1992, when she became a Principal Investigator of the Cardiovascular Research Center at Massachusetts General Hospital. She joined the Department of Cell Biology in 1996 and was appointed a Professor of Cell Biology at Harvard Medical School in 2000. She has been Elizabeth D. Hay Professor of Cell Biology at HMS since 2014. The research of Professor Yuan focuses on the molecular mechanisms that regulate cell death and the development of first-in-class small molecule inhibitors.



### Seamus J. Martin

[martinsj@tcd.ie](mailto:martinsj@tcd.ie)

Seamus Martin holds the Smurfit Professorship of Molecular Genetics at Trinity College Dublin, Ireland. He is interested in all aspects of programmed cell death (apoptosis), especially the links between cell death, inflammation and cancer. He was elected to The Royal Irish Academy of Sciences in 2006 and to the European Molecular Biology Organization (EMBO) in 2009. and is the editor-in-chief of The FEBS Journal.



### Suzanne Cory

[cory@wehi.edu.au](mailto:cory@wehi.edu.au)

Professor Suzanne Cory, molecular biologist and cancer researcher. Her laboratory investigates the role of different genetic changes in the development of leukemia and lymphoma. They also examine how these changes influence the response of cancer cells to chemotherapy. She was President of the Australian Academy of Science from 2010 to 2014 and serves on a number of councils and boards in Australia and overseas.



### David Huang

[huang\\_d@wehi.edu.au](mailto:huang_d@wehi.edu.au)

David Huang is a laboratory head at the Walter and Eliza Hall Institute (WEHI) of Medical Research in Australia and Professor in the Department of Medical Biology, Melbourne University. His interests are studying the molecular mechanisms that regulate cell death, understanding how deregulation of this process can lead to diseases such as cancer and how these can be targeted for improved therapies. His laboratory has made significant contributions to targeting the BCL2-regulated cell survival pathway for treating cancers. One of these is venetoclax which has been approved in many countries for treating patients with high-risk chronic lymphocytic leukemia (CLL).



### Jialing Lin

[jjaling-lin@ouhsc.edu](mailto:jjaling-lin@ouhsc.edu)

Associate Professor, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center. The objectives of his research are to determine the molecular mechanisms by which the Bcl-2 family proteins regulate the mitochondrial outer membrane permeability and apoptotic cell death, and to develop small molecule modulators of these proteins for treating diseases associated with insufficient or excessive apoptosis.